GLP-1 for Children: What the WHO Recommends and Why Age Changes Everything

Scroll through social media for a few minutes and you'll probably find a teenager talking about a GLP-1 medicine, or a parent asking whether a compounding pharmacy can make one for a child. Pediatric clinics hear the same questions every week. GLP-1 for children is no longer a fringe topic, and families want clear answers before they decide anything.

This post is for information only. It doesn't replace a conversation with your pediatrician or a pediatric endocrinologist, who can look at your child's growth, history, and lab results. Please don't start, stop, or change any medicine based on an article, including this one.

What the WHO guideline says, and what it doesn't

The World Health Organization published its first global guideline on GLP-1 therapies for obesity at the end of 2025. The document is aimed mainly at adults with obesity. Its recommendations are conditional, not strong, which means the decision depends on context, patient values, and what health systems can actually deliver.

In practice, "insufficient evidence" means studies haven't been large or long enough to answer a question with confidence. It doesn't prove a drug is harmful, and it doesn't prove it's safe. Read the exact passage on children and adolescents in the WHO document before you share it, because the wording matters more than any headline.

The guideline also treats GLP-1 medicines as one part of a wider care plan. Nutrition changes, physical activity, and ongoing follow-up stay at the foundation, and medication is added on top. The guideline covers several products, including semaglutide, liraglutide, and tirzepatide, and tirzepatide also acts on a second hormone receptor, so the products shouldn't be treated as identical.

Labels, age ranges, and off-label use

A medicine's label (the bula in Brazil) lists the approved indications and the age groups where studies support use. Off-label use means prescribing outside those indications or ages. It happens in medicine and can be justified in some cases, but it means the prescriber is relying on less direct evidence. Families should understand that difference from the start. The MounjaBlog notes on labels explain how to read these sections before you talk to the doctor.

Approved ages differ by active ingredient and by regulator. Some GLP-1 medicines have pediatric indications for obesity or type 2 diabetes in specific age ranges, and others have none. ANVISA, the European Medicines Agency, and the US FDA don't always agree, so check the current label in your country. Never rely on a friend's experience or a forum post for an age limit.

The SURPASS-PEDS trial studied tirzepatide in young people with type 2 diabetes. Read the published article for its design, population, and results, because outcomes depend on the endpoint and the comparison group. A trial in one age group and one condition doesn't automatically apply to every child.

Why age changes the risk picture

Growth plates and bone age

Children grow taller through growth plates near the ends of long bones. Medicines that change appetite or weight can affect growth patterns, so doctors track height over time. When it's unclear how far along a child is, a pediatrician may order a hand and wrist X-ray to estimate bone age. That estimate shows how much growth may still be ahead.

Puberty and Tanner stages

Puberty shifts body composition, fat distribution, and height quickly. A BMI that looks high at one stage can look different a year later. Tanner staging describes these changes and helps clinicians read weight and height in context. The WHO growth reference for ages 5 to 19 uses BMI-for-age percentiles, not the adult cutoffs many people remember.

Emotional development and eating behavior

The relationship with food forms during childhood and adolescence. Reduced appetite can look like progress while hiding restriction or disordered eating. Clinicians usually screen for eating disorders before any medication decision. For a teen already struggling with body image, a drug that suppresses appetite could worsen the pattern rather than help.

Safety signals that weigh more in young people

Nausea, vomiting, and diarrhea are common with these medicines. In children, dehydration can develop faster and can strain the kidneys. Any vomiting that won't stop, or any sign of dehydration, deserves prompt medical care.

Labels also list warnings about pancreatitis and gallbladder disease. Several GLP-1 products carry a boxed warning about thyroid C-cell tumors seen in animal studies, and they are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Some labels include warnings about mood changes and suicidal thoughts. Read the current warning sections for each product, and ask the prescriber what to monitor.

Compounded products and medicines bought online carry extra risks. Doses can be wrong, quality control can be missing, and ingredients can be unknown. Regulators in several countries have issued alerts about falsified and substandard GLP-1 products, so a cheaper source is not a safer one.

What guidance recommends before any medicine

A complete assessment comes first. That means family history (including thyroid cancer and endocrine tumors), a physical exam, laboratory tests, a mental health evaluation, and screening for eating disorders. The clinician also looks for other conditions that drive weight gain.

Multidisciplinary lifestyle care is the base. Nutrition support, psychology, adapted physical activity, and family involvement are described in the guideline as the foundation of care, not an afterthought. Bring a written record of weight and height over time, symptoms, diet history, every medicine and supplement your child takes, and your questions in writing. A guide on organizing questions for the doctor at MounjaBlog can help you structure that list before the appointment.

When to seek care without delay, and where to read more

Some situations need urgent attention and shouldn't wait for the next visit. Seek care right away if your child has any of these:

• Severe or worsening abdominal pain
• Vomiting that won't stop or prevents drinking fluids
• Signs of dehydration, such as very dark urine, dizziness, or dry mouth
• Sudden mood changes or any talk of self-harm
• Skipping meals, severe food restriction, or fear of eating

For further reading, the MounjaBlog team publishes material on safety, age, and questions to bring to the clinic. Use it to prepare, then take your findings to your child's healthcare team, who can judge what applies to your child.

FAQ

Is there a minimum age for GLP-1 medicines?

There isn't one answer for every product. The minimum age depends on the specific medicine, the condition, and the country. Check the current label and talk to a pediatric specialist before drawing any conclusion.

If other teens use it, does that mean it's safe?

Not necessarily. Small and short studies can't answer questions about long-term safety in a body that is still growing. Experience shared online doesn't replace controlled evidence.

Can a pediatrician start a GLP-1 for my child?

A specialist may consider certain medicines in specific cases after a full evaluation, sometimes off-label. That decision belongs to the clinician and the family together, and it should never be made by buying a product on your own.

Does a pediatric trial prove it works for every child?

No. Trials enroll specific age groups and conditions. Results can guide a conversation, but they don't promise the same outcome for every child, and they don't remove the need for individual assessment.

Sources

• World Health Organization (WHO), website with GLP-1 therapies guideline for obesity
• WHO Growth reference data for 5 to 19 years
• US Food and Drug Administration (FDA), drug labeling and safety communications
• European Medicines Agency (EMA), medicine information
• ANVISA, Agência Nacional de Vigilância Sanitária